BRIEF published on 06/17/2025 at 07:05, 1 year 2 months ago Innate Pharma to Participate in Key Investor Conferences Biotechnology Investor Conferences Healthcare Immunotherapy Innate Pharma
BRIEF published on 06/17/2025 at 07:05, 1 year 2 months ago Innate Pharma participera à des conférences d'investisseurs clés Biotechnologie Immunothérapie Soins De Santé Conférences D'investisseurs Innate Pharma
PRESS RELEASE published on 06/17/2025 at 07:00, 1 year 2 months ago Inside Information / Other news releases Innate Pharma to participate in H.C. Wainwright and Wolfe Research healthcare conferences showcasing their innovative immunotherapy approaches. Global biotech company expanding portfolio Biotechnology Immunotherapy Clinical-stage Innate Pharma Healthcare Conferences
BRIEF published on 06/13/2025 at 07:05, 1 year 2 months ago Innate Pharma's IPH6501 Shows Potential in Lymphoma Treatment Innate Pharma Preclinical Results IPH6501 Lymphoma R-CHOP
BRIEF published on 06/13/2025 at 07:05, 1 year 2 months ago L'IPH6501 d'Innate Pharma montre un potentiel dans le traitement du lymphome Innate Pharma Résultats Précliniques IPH6501 R-CHOP Lymphome
PRESS RELEASE published on 06/13/2025 at 07:00, 1 year 2 months ago Inside Information / Other news releases Innate Pharma highlights preclinical antitumor activity of IPH6501 in DLBCL and FL at the 2025 EHA Congress, presenting potent efficacy in in vitro and in vivo models with R-CHOP combination Preclinical Data EHA Congress Innate Pharma Antitumor Activity IPH6501
BRIEF published on 05/13/2025 at 07:05, 1 year 3 months ago Innate Pharma publie ses résultats du premier trimestre 2025 Résultats Financiers Essais Cliniques Innate Pharma Investissement Sanofi Lacutamab FDA
BRIEF published on 05/13/2025 at 07:05, 1 year 3 months ago Innate Pharma Reports First Quarter 2025 Results Financial Results Clinical Trials Innate Pharma Sanofi Investment Lacutamab FDA
PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 3 months ago Informations privilégiées / Communiqué sur comptes, résultats Innate Pharma annonce ses résultats financiers du premier trimestre 2025 et les avancées de son portefeuille, incluant des investissements et des études cliniques. Une conférence téléphonique est prévue à 14h00 CEST Résultats Financiers Conférence Téléphonique Portefeuille Études Cliniques Innate Pharma
PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 3 months ago Inside Information / News release on accounts, results Innate Pharma reports Q1 2025 business update with €15 million investment by Sanofi, FDA Breakthrough Therapy Designation for lacutamab, and cash position of €72.5 million FDA Financial Results Sanofi Innate Pharma Q1 2025
Published on 09/12/2026 at 02:35, 12 hours 1 minute ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 36 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 31 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 17 hours 11 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 36 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 7 hours 6 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 21 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 26 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 52 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 21 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 19 hours ago Availability of the 2026 Interim Financial Report
